EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 64 / Numéro 3 (Mai-Juin 2009) Thérapie, 64 3 (2009) 145-148 Références
Accès gratuit
Numéro
Thérapie
Volume 64, Numéro 3, Mai-Juin 2009
Page(s) 145 - 148
Section Pharmacologie Clinique/Clinical Pharmacology
DOI https://doi.org/10.2515/therapie/2009020
Publié en ligne 13 août 2009
  1. Cummings JF. Alzheimer's disease. N Engl J Med 2004; 351(1): 56-67 [Google Scholar]
  2. Morris JC. Dementia update 2005. Alzheimer Dis Assoc Disord 2005; 19: 100-17 [CrossRef] [PubMed] [Google Scholar]
  3. CHMP 2008. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. http://www.emea.europa.eu/pdfs/human/ewp/055395en.pdf [Google Scholar]
  4. EMEA. Note for guidance on medicinal products in the treatment of Alzheimer's disease. 1997. http://www.emea.europa.eu/ [Google Scholar]
  5. FDA. Guidelines for the clinical evaluation of antidementia drugs, first draft, November 8, 1990. http://www.fda.gov [Google Scholar]
  6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 2007; 6: 734-46 [Google Scholar]
  7. Shaw LM, Korecka M, Clark CM, et al. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics Nature reviews. Drug Discovery 2007; 6: 295-303 [Google Scholar]
  8. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004: 1: 213-25 [Google Scholar]
  9. Risner ME, Saunders AM, Altman JFB, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Rosiglitazone in Alzheimer's disease study group. The Pharmacogenomics Journal 2006; 6, 246-54 [Google Scholar]
  10. Schneider L. AD2000: donepezil in Alzheimer's disease. Lancet 2004; 363: 2100-1 [CrossRef] [PubMed] [Google Scholar]
  11. Vellas B, Andrieu S, Sampaio C, et al. Endpoints for trials in Alzheimer's disease: a European task force consensus Lancet Neurol 2008; 7: 436-50 [Google Scholar]
  12. Harrison J, Minassian SL, Jenkins L, et al. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007; 64(9): 1323-9 [Google Scholar]
  13. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's disease assessment scale that broaden its scope: the Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2): S13-S21 [Google Scholar]
  14. Galasko D, Bennett D, Sano M, et al. A inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997; 11 (Suppl 2): 533-9 [Google Scholar]
  15. Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 1997; 9 (Suppl 1): 163-5 [Google Scholar]